Palatin Technologies, Inc.
As of Oct 22, 2026, Palatin Technologies is in Stage 1, the basing phase, now in week 5 (since Sep 22, 2026). It closed at $5.51, 80.3% below its 52-week high and below its 200-day average, which is falling.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is PTN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PTN among Biotechnology224th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …224 | PTN | Stage 1 · wk 5 | 44 | −46.3% |
Palatin Technologies: quick answers
What stage is Palatin Technologies in?
As of Oct 22, 2026, Palatin Technologies (PTN) is in Stage 1, the basing phase. It entered Stage 1 on Sep 22, 2026 and is in week 5. What the four stages mean
Is Palatin Technologies in an uptrend?
Not yet. Palatin Technologies is in Stage 1, a base that can come before an uptrend. It trades 61.7% below its 200-day average, which is falling.
How far is Palatin Technologies from its 52-week high?
Palatin Technologies closed at $5.51 on Oct 22, 2026, 80.3% below its 52-week high of $28.00. Its 52-week low is $5.51.
How has Palatin Technologies performed over the past year?
As of Oct 22, 2026, Palatin Technologies is down 14.2% over the past year and down 65.7% so far in 2026.
Which sector and industry is Palatin Technologies in?
Palatin Technologies is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.